Holding(s) in Company

24 May 2006 15:20

Cambridge Antibody Tech Group PLC24 May 2006 NOTIFICATION OF MAJOR INTERESTS IN SHARES 1. Name of company CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC 2. Name of shareholder having a major interest CREDIT SUISSE 3. Please state whether notification indicates that it is in respect of holdingof the shareholder named in 2 above or in respect of a non-beneficial interestor in the case of an individual holder if it is a holding of that person'sspouse or children under the age of 18 CREDIT SUISSE SECURITIES (EUROPE) LIMITED NOT KNOWN CREDIT SUISSE INTERNATIONAL NOT KNOWN 4. Name of the registered holder(s) and, if more than one holder, the number ofshares held by each of them CREDIT SUISSE SECURITIES (EUROPE) LIMITED 2,735,281 CREDIT SUISSE INTERNATIONAL 9 5. Number of shares / amount of stock acquired NOT DISCLOSED 6. Percentage of issued class N/A 7. Number of shares / amount of stock disposed N/A 8. Percentage of issued class N/A 9. Class of security ORDINARY 10 PENCE SHARES 10. Date of transaction 19 MAY 2006 11. Date company informed 24 MAY 2006 12. Total holding following this notification 2,735,290 13. Total percentage holding of issued class following this notification 5.14% 14. Any additional information THOSE CREDIT SUISSE COMPANIES WHICH ARE DIRECT OR INDIRECT HOLDING COMPANIES OFCREDIT SUISSE SECURITIES (EUROPE) LIMITED AND CREDIT SUISSE INTERNATIONAL ARE,UNDER THE TERMS OF SECTION 203 OF THE ACT, EACH INTERESTED BY ATTRIBUTION IN ANYSHARES IN WHICH CREDIT SUISSE SECURITIES (EUROPE) LIMITED AND CREDIT SUISSEINTERNATIONAL ARE INTERESTED. 15. Name of contact and telephone number for queries JUSTIN HOSKINS 01223 898589 16. Name and signature of authorised company official responsible for makingthis notification JUSTIN HOSKINS, COMPANY SECRETARY Date of notification 24 MAY 2006 The FSA does not give any express or implied warranty as to the accuracy of thisdocument or material and does not accept any liability for error or omission.The FSA is not liable for any damages (including, without limitation, damagesfor loss of business or loss of profits) arising in contract, tort or otherwisefrom the use of or inability to use this document, or any material contained init, or from any action or decision taken as a result of using this document orany such material. This information is provided by RNS The company news service from the London Stock Exchange